Korlym™ (mifepristone), the First Approved Medication for Patients with...
Corcept Therapeutics (NASDAQ:CORT) announced that it would be ready to ship Korlym to patients by April 11th, three weeks ahead of the company’s previously announced launch date. “Cushing’s syndrome...
View ArticleNovartis drug Signifor approved in the EU as the first medication to treat...
* Reuters is not responsible for the content in this press release. Wed Apr 25, 2012 Novartis International AG / Novartis drug SigniforR approved in the EU as the first medication to treat patients...
View ArticleCushing’s on Capitol Hill: Cushing’s Awareness Challenge
Earlier this year, I got this email: Good morning Mary: I hope everything is well. I would like to invite you to join us at the Rare Disease Congressional Caucus briefing scheduled for April 2013. The...
View ArticleNIH: An Open-Label Study of The Safety, Pharmacokinetics and Pharmacodynamics...
This study is currently recruiting participants. Summary Number 13-CH-0170 Sponsoring Institute National Institute of Child Health and Human Development (NICHD) Recruitment Detail Type: Participants...
View ArticlePituitary ACTH Hypersecretion (Cushing’s Disease)
Browse Complete Report with TOC: http://www.reportbazzar.com/product/pituitary-acth-hypersecretion-cushings-disease-pipeline-review-h1-2015/ Summary This report provides comprehensive information on...
View ArticleClinical Trial for levoketoconazole
This trial is testing the safety and effectiveness of a new investigational drug for the treatment of Cushing’s Syndrome. Under the supervision of qualified physicians, cortisol levels and symptoms of...
View ArticleGlobal Cushing’s Syndrome Market Size 2015
Cushing’s as money makers for drug companies :( ~~~ Steroidogenesis inhibitors were responsible for approximately 28% of total drug sales in the 6MM in 2013, equating to around $50m. As a consequence...
View ArticleOsilodrostat for Cushing’s
The study looked at a drug to treat Cushing’s disease. The article, in the journal Pituitary, is called Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in...
View ArticleRecruitment for Cushing’s Syndrome Clinical Study
DESCRIPTION This trial is testing the safety and effectiveness of a new investigational drug for the treatment of Cushing’s Syndrome. Under the supervision of qualified physicians, cortisol levels and...
View ArticleExperimental Drug Improves Cushing’s Disease
International phase 3 trial is largest study ever of rare endocrine disorder A new investigational drug significantly reduced urinary cortisol levels and improved symptoms of Cushing’s disease in the...
View Article
More Pages to Explore .....